Amoy Diagnostics (300685) Fundamentals 2026 — P/E 19.5x, Revenue Analysis | SniperIQ
Amoy Diagnostics (300685) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ¥6.8B, trading at ¥17.53 on the SHZ. This SniperIQ fundamentals page covers Amoy Diagnostics's valuation (P/E 19.5x, P/B 3.3x), profitability (net margin 30.0%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Amoy Diagnostics's market cap?
Amoy Diagnostics (300685) has a market capitalization of approximately ¥6.8B, trading at ¥17.53 on the SHZ. Market cap moves with the live share price.
What is Amoy Diagnostics's P/E ratio?
Amoy Diagnostics's trailing twelve-month P/E ratio is 19.5x, with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Amoy Diagnostics?
Amoy Diagnostics runs a net profit margin of 30.0%, a gross margin of 82.4%, and an operating margin of 35.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Amoy Diagnostics generate?
Amoy Diagnostics reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥361M and earnings per share (EPS) of 0.91. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Amoy Diagnostics pay a dividend?
Amoy Diagnostics offers a trailing dividend yield of about 2.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Amoy Diagnostics financially healthy?
Amoy Diagnostics carries a debt-to-equity ratio of 0.10x and a current ratio of 15.14x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Amoy Diagnostics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Amoy Diagnostics (300685) the key facts are: market cap ¥6.8B, P/E 19.5x, revenue ¥1.2B, 52-week range 15.62-26.15. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Amoy Diagnostics's full fundamentals live
Get Amoy Diagnostics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.